A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Open-label, multicenter study of imatinib (400mg/die p.o.)in patients with advanced
gastrointestinal stromal tumors. Patients will be treated for up to 12 months. Data regarding
its best clinical use in terms of tumor response, survival, tolerability and safety profile
will be prospectively collected.